Outlook Therapeutics (OTLK) EBIT: 2015-2020
Historic EBIT for Outlook Therapeutics (OTLK) over the last 6 years, with Sep 2020 value amounting to -$10.0 million.
- Outlook Therapeutics' EBIT rose 21.10% to -$10.0 million in Q3 2020 from the same period last year, while for Sep 2020 it was -$36.8 million, marking a year-over-year decrease of 1.49%. This contributed to the annual value of -$71.7 million for FY2024, which is 34.97% down from last year.
- As of Q3 2020, Outlook Therapeutics' EBIT stood at -$10.0 million, which was up 15.70% from -$11.9 million recorded in Q2 2020.
- Over the past 5 years, Outlook Therapeutics' EBIT peaked at -$2.9 million during Q3 2017, and registered a low of -$22.0 million during Q2 2016.
- Over the past 3 years, Outlook Therapeutics' median EBIT value was -$8.2 million (recorded in 2019), while the average stood at -$9.1 million.
- As far as peak fluctuations go, Outlook Therapeutics' EBIT spiked by 82.13% in 2017, and later crashed by 326.49% in 2018.
- Outlook Therapeutics' EBIT (Quarterly) stood at -$17.8 million in 2016, then spiked by 82.13% to -$3.2 million in 2017, then tumbled by 222.58% to -$10.3 million in 2018, then climbed by 20.21% to -$8.2 million in 2019, then grew by 21.10% to -$10.0 million in 2020.
- Its EBIT stands at -$10.0 million for Q3 2020, versus -$11.9 million for Q2 2020 and -$6.8 million for Q1 2020.